title: Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation.
abstract: Cytomegalovirus (CMV) is an important cause of morbidity and mortality in children who have received organ transplants. Patients have been reported to be at differential risk for CMV disease based on the serostatus of the donor and recipient with highest risk reported for CMV seronegative recipients who receive an organ from a CMV seropositive donor. Prophylaxis with ganciclovir and/or oral valganciclovir is reasonable to attempt to prevent CMV infections. A hybrid strategy bridging prophylaxis and pre-emptive therapy appears to be emerging as an additional method to prevent CMV disease. However, there is no agreement on the optimal schedule of testing, duration and dosing of antiviral medications or the role of immunoglobulin therapy. This manuscript will review the most recent literature and recommendations for the prophylaxis and treatment of CMV infections and disease in pediatric transplant recipients. Multicenter, randomized, clinical studies involving several pediatric transplant centers are needed to determine the best strategies to prevent and treat CMV infections in these patients.
authors.affiliation: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA. judy.martin@chp.edu
authors.forename: Judith M
authors.initials: JM
authors.lastname: Martin
authors.forename: Lara A
authors.initials: LA
authors.lastname: Danziger-Isakov
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D001706:Biopsy; D002648:Child; D002986:Clinical Trials as Topic; D003587:Cytomegalovirus / Q000378:metabolism*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D007107:Immune System; D007136:Immunoglobulins / Q000627:therapeutic use; D016377:Organ Transplantation / Q000379:methods*; D011183:Postoperative Complications; D012306:Risk; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007136:Immunoglobulins